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Sir,
Asahina et al (2006) report the second prospective trial of
gefitinib as front-line therapy for epidermal growth factor receptor
(EGFR)-mutant metastatic non-small-cell lung cancer (NSCLC).
The impressive results of these initial 32 patients from two
separate Japanese groups is unheard in NSCLC and shows the
promise of patient selection for use of targeted therapy (Asahina
et al, 2006; Inoue et al, 2006). However, it is still elusive if different
types of EGFR tyrosine kinase mutations have different clinical
impact. The two most common activating mutations seen in
patients are exon 19 deletions and the exon 21 L858R. In the largest
retrospective cohorts of patients from two United States centres
who followed EGFR-mutant NSCLC patients given tyrosine kinase
inhibitors (gefitinib or erlotinib) as first to third-line therapy,
it was observed that patients with exon 19 deletions had a
significantly improved time to progression and overall survival
when compared with L858R patients (Jackman et al, 2006; Riely
et al, 2006). In both reports, patients with exon 19 in-frame
deletions had at least double the progression-free and overall
survival of the group with the L858R mutation.
In the two Japanese prospective trials, the response rates for
both mutations were not significantly different. Inoue et al (2006)
reported response rates of 67 and 86% for exon 19 deletions and
L858R mutants, respectively. In the current Asahina et al (2006)
article in the British Journal of Cancer, the response rates were 83%
for exon 19 deletions and 67% for L858R patients. The time to
progression in the later trial seems to be similar in both different
mutant cohorts and, of note, one of the patients with the most
prolonged response (over 13 months) had an L858R mutation
(Asahina et al, 2006).
Further data collection from the ongoing prospective trials of
EGFR tyrosine kinase inhibitors (Asahina et al, 2006; Inoue et al,
2006; Paz-Ares et al, 2006) will determine if there is a real clinical
difference in response and survival between the two most common
EGFR mutations. The verdict is still out if EGFR activating
mutations in NSCLC are not created equal.
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